Sanofi to review its new eczema drug amlitelimab

Corvus shares nearly triple on positive data for eczema pill

An immune drug developer raises $50M to finance its eczema drug testing

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study

J&J eyes $100B in sales amid gains for cancer, immune drugs

Alumis soars as TYK2 drug hits mark in psoriasis trials

Galapagos TYK2 drug hits goal in one trial, misses in another

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

Roundtable Discussion: Achieving Sustainable Pricing in Dermatology: Balancing Innovation with Europe’s Cost-Containment Pressures

By | 15 January 2026

How do companies price new therapies when topicals are benchmarked against corticosteroids?
How does biosimilar competition reshape pricing windows for innovators?
What evidence creates justification for premium pricing in chronic inflammatory diseases?